Senores Pharmaceuticals Share Price

Senores Pharmaceuticals Limited is a research-driven pharmaceutical company engaged in developing, manufacturing, and commercializing complex generics and specialty pharmaceutical products. The company focuses on niche and underpenetrated segments in the global pharmaceutical market, including critical-care injectables and active pharmaceutical ingredients (APIs). The Senores Pharmaceuticals share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Senores Pharmaceuticals stock price often mirrors shifts in global drug demand, the company’s product pipeline, and investor views on the pharmaceutical sector’s growth prospects. Factors such as the pace of regulatory approvals, manufacturing capabilities, and tender wins influence near-term market valuation of the Senores Pharmaceuticals share price. Understanding the Senores Pharmaceuticals live share price can be instrumental for market participants. 

Monitoring the Senores Pharmaceuticals live share price gives a real-time view of trading activity. Constant observation of the Senores Pharmaceuticals share price today helps investors understand real-time market sentiment, price volatility, and trading behavior in response to key announcements. The Senores Pharmaceuticals stock price is a reflection of its earnings potential. 

Senores Pharmaceuticals Limited Company Fundamentals 

A. Company Background 

Senores Pharmaceuticals Limited was incorporated in 2017. The company’s registered office is located in Ahmedabad, Gujarat. Senores Pharmaceuticals is engaged in the development, manufacturing, and commercialization of complex generics and specialty pharmaceutical products, focusing on niche and underpenetrated segments in the global pharmaceutical market. The company initially focused on building an integrated business model encompassing in-licensing, contract development and manufacturing, and its own branded product sales. Senores has focused on regulated markets like the United States, Canada, and the UK for its commercial operations. Over the years, the company has expanded its portfolio to include critical-care injectables and APIs. 

B. Product Lines 

• Critical-care injectables for hospital use 

• Active Pharmaceutical Ingredients (APIs) for various therapeutic segments 

• Complex generic formulations for regulated markets 

• In-licensed specialty pharmaceutical products 

• Contract Development and Manufacturing Organization (CDMO) services 

• Branded generic products for domestic and international markets 

C. Company Revenue Model 

• Primary revenue from sale of pharmaceutical formulations and APIs 

• Revenue from CDMO services for third-party pharmaceutical companies 

• Volume-driven revenue based on quantities sold to distributors 

• Revenue from branded product sales in regulated markets 

• Licensing and royalty income from intellectual property 

• In-licensing partnerships contributing to new product revenue 

• Expansion into new therapeutic areas for revenue diversification 

• Contract research and manufacturing services 

• Government policy changes and drug pricing mechanisms influencing revenue 

D. Geographic Presence 

• Strong presence across India with registered office in Ahmedabad, Gujarat 

• Operations cover major domestic pharmaceutical markets 

• Focus on regulated markets including the United States, Canada, and United Kingdom 

• Serves emerging markets across Asia, Africa, and Latin America 

• Export-oriented business model with significant overseas revenue 

• Primary operations based out of India 

• Continuous expansion of partner networks in new international territories 

E. Key Milestones 

• 2017: Incorporated as Senores Pharmaceuticals Private Limited 

• 2024: Successfully listed on stock exchanges after IPO 

• Ongoing: Expansion of product portfolio in regulated markets 

F. Industry Perspective 

Senores Pharmaceuticals operates in the Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) segment and the specialty generics market. Globally, the pharmaceutical contract manufacturing market was valued at approximately USD 140-145 billion in 2025. The Indian CRDMO market is poised to grow at a CAGR of 13.4% over 2024-2029. The India CDMO market size was valued at USD 17.51 Billion in 2024 and is expected to reach USD 37.71 Billion by 2030 with a CAGR of 13.60%. Other estimates project an 18% CAGR for the sector between FY25 and FY30, fueled by a visible drug pipeline and Big Pharma’s “China+1” diversification strategy. R&D spending by pharmaceutical companies globally is expected to grow at a 3.3% CAGR from 2023 to 2028. India’s pharmaceutical exports are nearing USD 30 billion, with CDMOs playing a central role in driving the sector’s next phase of growth. 

Senores Pharmaceuticals Limited Stock Market Presence: Listings & Index Representation 

Senores Pharmaceuticals is listed on both the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE). The company’s NSE symbol is SENORES, and its BSE scrip code is 544319. Its listing on both exchanges ensures that the Senores Pharmaceuticals share price is accessible to a broad spectrum of investors. The company was listed in December 2024. Senores Pharmaceuticals is a constituent of the BSE IPO Index and the Nifty IPO Index. Being part of these indices enhances the liquidity and visibility of the Senores Pharmaceuticals share price, as index tracking funds often adjust their portfolios in line with constituent changes. It also allows investors to benchmark the Senores Pharmaceuticals share price against broader market trends. 

Senores Pharmaceuticals Limited Stock Performance and Share Price History 

The Senores Pharmaceuticals share price has exhibited significant volatility since its listing in December 2024. The Senores Pharmaceuticals share price recorded a positive total return of approximately 62.67% over the last 1 year. The Senores Pharmaceuticals share price reached a 52-week high of 876.50 and a 52-week low of 435.25, indicating a wide trading range. The Senores Pharmaceuticals share price delivered a strong return in early 2025. The Senores Pharmaceuticals share price has shown a 1-month return of approximately 18.74% and a 3-month return of 13.14%, indicating continued momentum. 

The Senores Pharmaceuticals stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company announced strong profit growth, the Senores Pharmaceuticals stock price showed a positive reaction. The Senores Pharmaceuticals share price has shown a pattern of strong positive momentum in periods following the announcement of new product approvals. The Senores Pharmaceuticals share price has shown a year-to-date return reflecting volatility. The Senores Pharmaceuticals stock price has shown a 1-year return of 62.67%. 

The Senores Pharmaceuticals share price has shown distinct seasonal patterns, although its history is short. The best performing month historically was March 2025. The Senores Pharmaceuticals share price reached its all-time high of 876.50 before moderating. The Senores Pharmaceuticals stock price has been evaluated in the context of its growth potential. The Senores Pharmaceuticals share price has shown its shortest track record, given its recent listing. 

Senores Pharmaceuticals Limited Investor Relevance and Role in Portfolio 

Senores Pharmaceuticals holds a niche position for portfolio investors seeking exposure to India’s specialty pharma and CDMO growth story. The company’s focus on complex generics and integrated manufacturing aligns it with the “China+1” narrative in global pharmaceutical supply chains. The Senores Pharmaceuticals share price often reflects market confidence in this theme. Institutional stakeholders play a crucial role, with notable long-term investment entities such as HDFC Mutual Fund, Nippon India Mutual Fund, Kotak Mahindra Mutual Fund, Quant Mutual Fund, ICICI Prudential Mutual Fund, SBI Mutual Fund, Axis Mutual Fund, Motilal Oswal Mutual Fund, Franklin Templeton Mutual Fund, and UTI Mutual Fund among key shareholders. 

Mutual fund holders of Senores Pharmaceuticals encompass those that seek exposure in the small-cap pharma space, including ICICI Prudential Pharma Healthcare And Diagnostics Fund, Bandhan BSE Healthcare Index Fund, HDFC Small Cap Fund, Nippon India Small Cap Fund, Kotak Small Cap Fund, Quant Small Cap Fund, Motilal Oswal Midcap Fund, Axis Small Cap Fund, Franklin India Smaller Companies Fund, and UTI Healthcare Fund. 

Based on data, Senores Pharmaceuticals exhibits varying levels of beta and volatility across different time horizons. The long-term beta stands at 1.20. On a daily basis, the one-month daily beta is 0.85 and the three-month daily beta is 0.90. Moving to weekly observations, the one-year weekly beta is 1.10, the two-year weekly beta is 1.30, and the two-week two-year range stands at 1.25. The monthly two-year beta is 1.80. Supporting statistics such as mean values ranging from 450.00 to 800.00 and standard deviations from 15.00 to 30.00 further indicate variability. 

Senores Pharmaceuticals Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Senores Pharmaceuticals lies in the Indian pharmaceutical CDMO and specialty generics industry. Competitors include Laurus Labs, Divi’s Laboratories, Jubilant Pharmova, Gland Pharma, Syngene International, and Neuland Laboratories. 

Senores Pharmaceuticals earnings have shown exceptional growth in recent quarters, driven by a strong revenue mix. The company’s net income has seen a significant increase, with PAT surging 131% in Q2 FY26 and 105% in Q3 FY26. The company’s earnings power has increased post-listing, moving from a low-profit base to high growth. 

Senores Pharmaceuticals EPS has shown a strong increasing trend since its listing. The diluted EPS has grown significantly, with the TTM EPS reaching over 25. The EPS growth rate has been robust YoY in recent quarters as the company’s revenue mix has improved and operating leverage has increased. 

Senores Pharmaceuticals P/E ratio is currently trading at a premium compared to its peers and the broader pharma sector, reflecting its high-growth expectations. The TTM P/E ratio stands around 34-40x, with a forward P/E of 25-26x. 

Senores Pharmaceuticals market cap has witnessed a significant re-rating post its IPO. The company’s market cap has grown substantially from its implied IPO valuation to over ₹3,800 crore, as of December 2025. This increase in Senores Pharmaceuticals market cap mirrors the sharp appreciation in the Senores Pharmaceuticals share price. 

Summary 

Senores Pharmaceuticals is a specialty pharma company listed on the NSE and BSE. The Senores Pharmaceuticals share price reflects market sentiment regarding its complex generic portfolio and growth in the CDMO sector. Its recent listing makes it an emerging pick in the small-cap pharma space. Its market presence is linked to the “China+1” narrative.